Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Doki, Noriko  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, et al. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. Cytotherapy. 2023.
Ishida H, Shimada H, Tanizawa A, Shimazu Y, Tachibana T, Doki N, Ara T, Matsuo Y, Nara M, Toubai T, et al. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era. Am J Hematol. 2023.
Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, et al. Author Correction: A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023;3(1):89.
C
Shingai N, Mizumaki H, Najima Y, Yamada Y, Tran DCao, Haraguchi K, Toya T, Okuyama Y, Doki N, Nannya Y, et al. Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria. Front Immunol. 2023;14:1329403.
Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, et al. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplantation predicts relapse in patients with acute myeloid leukemia without complete remission. Leuk Lymphoma. 2015:1-14.
Hanajiri R, Kobayashi T, Yoshioka K, Watanabe D, Watakabe K, Murata Y, Hagino T, Seno Y, Najima Y, Igarashi A, et al. Central nervous system infection following allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2016.
Shirane S, Najima Y, Fukushima K, Sekiya N, Funata N, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, et al. Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature. J Infect Chemother. 2022.
Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida S-I, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, et al. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs. Haematologica. 2023.
Yagi Y, Kanemasa Y, Ohigashi A, Morita Y, Tamura T, Nakamura S, Otsuka Y, Kishida Y, Kageyama A, Shimizuguchi T, et al. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report. Medicine (Baltimore). 2021;100(44):e27733.
Doki N, Ohashi K, Oshikawa G, Kobayashi T, Kakihana K, Sakamaki H. Clinical Outcome of Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL): Experience From a Single Institution. Pathol Oncol Res. 2013.
Konuma T, Kondo T, Mizuno S, Doki N, Aoki J, Fukuda T, Tanaka M, Sawa M, Katayama Y, Uchida N, et al. Conditioning intensity for allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with poor-prognosis cytogenetics in first complete remission. Biol Blood Marrow Transplant. 2019.
Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, et al. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023;3(1):67.
D
Tamaki M, Kameda K, Kimura S-I, Harada N, Uchida N, Doki N, Tanaka M, Ikegame K, Sawa M, Katayama Y, et al. Deletion of Y-chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Adv. 2022.
Toya T, Mizuno K, Sakurai M, Kato J, Mori T, Doki N, Masuda S, Aotsuka N, Tsukamoto S, Sakaida E, et al. Differential Clinical Impact of Letermovir Prophylaxis According to Graft Sources: a KSGCT Multicenter Retrospective Analysis. Blood Adv. 2023.
E
Imahashi N, Kurita N, Konuma T, Takahashi S, Nishida T, Tanaka M, Nakamae H, Kawakita T, Ota S, Doki N, et al. Effect of conditioning regimens and GVHD prophylaxis on the outcomes of umbilical cord blood transplantation performed with cyclophosphamide/total-body irradiation-based regimens. Transplant Cell Ther. 2023.
Kanda Y, Doki N, Kojima M, Kako S, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, et al. Effect of cryopreservation in unrelated bone marrow and peripheral blood stem cell transplantation in the era of the COVID-19 pandemic. An update from the Japan Marrow Donor Program. Transplant Cell Ther. 2022.
Tanaka K, Toyota S, Akiyama M, Wakimoto N, Nakamura Y, Najima Y, Doki N, Kakihana K, Igarashi A, Kobayashi T, et al. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematol. 2019;141(2):111-118.
Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Kanda Y, Doki N, Nishiwaki K, Miwa A, et al. Efficacy of autologous stem cell transplantation for patients with myeloma having suboptimal response: A multicenter retrospective analysis. Transplant Cell Ther. 2023.
Shingai N, Ota A, Kato K, Kondo K, Sadaga Y, Kato C, Sakai S, Kambara Y, Nabe Y, Asano K, et al. Elevation of urinary liver-type fatty acid-binding protein is a harbinger of poor patient prognosis after allogeneic stem cell transplantation. Transplant Cell Ther. 2023.
Kurosawa S, Sekiya N, Doki N, Yaguchi T, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, Yoshifuji K, et al. The emergence of rare nocardiosis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. Int J Infect Dis. 2019.
F
Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, et al. Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplantation and its differences among disease risk or types. Biol Blood Marrow Transplant. 2020.
Jo T, Ueda T, Akahoshi Y, Kondo T, Uchida N, Tanaka M, Nakamae H, Doki N, Ota S, Sawa M, et al. First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia. Br J Haematol. 2024.
Kurihara K, Sadato D, Najima Y, Hirama C, Haraguchi K, Kato K, Kondo K, Sadaga Y, Kato C, Sakai S, et al. [FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with PTPN11 mutation at relapse]. Rinsho Ketsueki. 2024;65(2):63-68.
H
Shimomura Y, Kitamura T, Konuma T, Nakaya Y, Doki N, Sawa M, Nakamae H, Eto T, Nishida T, Ohigashi H, et al. Hematopoietic stem cell transplantation from haploidentical offspring donors using post-transplant cyclophosphamide versus human leukocyte antigen-matched siblings in older patients with myelodysplastic syndrome. Am J Hematol. 2023.
Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, et al. High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. Hemasphere. 2023;7(6):e899.

Pages